1. Home
  2. LITE vs IKT Comparison

LITE vs IKT Comparison

Compare LITE & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lumentum Holdings Inc.

LITE

Lumentum Holdings Inc.

HOLD

Current Price

$878.45

Market Cap

78.1B

ML Signal

HOLD

Logo Inhibikase Therapeutics Inc.

IKT

Inhibikase Therapeutics Inc.

N/A

Current Price

$2.49

Market Cap

220.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LITE
IKT
Founded
2015
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
78.1B
220.5M
IPO Year
2015
2020

Fundamental Metrics

Financial Performance
Metric
LITE
IKT
Price
$878.45
$2.49
Analyst Decision
Buy
Strong Buy
Analyst Count
15
5
Target Price
$645.43
$5.00
AVG Volume (30 Days)
4.3M
391.2K
Earning Date
05-05-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.76
EPS
N/A
N/A
Revenue
$1,247,700,000.00
N/A
Revenue This Year
$79.88
N/A
Revenue Next Year
$66.61
N/A
P/E Ratio
N/A
N/A
Revenue Growth
24.57
N/A
52 Week Low
$144.52
$1.33
52 Week High
$1,085.68
$2.61

Technical Indicators

Market Signals
Indicator
LITE
IKT
Relative Strength Index (RSI) 48.56 58.17
Support Level $804.35 $2.31
Resistance Level $958.50 $2.53
Average True Range (ATR) 58.68 0.11
MACD -6.62 -0.01
Stochastic Oscillator 28.81 63.24

Price Performance

Historical Comparison
LITE
IKT

About LITE Lumentum Holdings Inc.

Lumentum Holdings Inc is a California-based technology firm. The company provides two types of optical and photonic products: optical components that are used in telecommunications networking equipment, and commercial lasers for manufacturing, inspection, and life-science lab uses. Its segments are Optical Communications and Commercial Lasers. The firm is also expanding into new optical applications, such as 3-D sensing laser diode for consumer electronics. It generates maximum revenue from the OpComms segment. The OpComms segment products include a wide range of components, modules, and subsystems to support customers including carrier networks for access (local), metro (intracity), long-haul, and submarine (undersea) applications.

About IKT Inhibikase Therapeutics Inc.

Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.

Share on Social Networks: